Story

GenFleet Initiates Phase III Trial for KRAS G12D Inhibitor in Lung Cancer

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
GenFleet Initiates Phase III Trial for KRAS G12D Inhibitor in Lung Cancer
Text size
Background

GenFleet Therapeutics (02595.HK) has initiated a Phase III registrational clinical trial in China for GFH375, its oral KRAS G12D inhibitor, as a treatment for non-small cell lung cancer (NSCLC), according to a company announcement. The enrollment of the first patient marks a key milestone, launching the second pivotal study for the drug candidate.

Trial Design and Scope

The study, named "Qilin-Fei 01," is a multi-center, open-label, randomized controlled trial that will evaluate the efficacy of GFH375 monotherapy compared to docetaxel. It is designed for patients with KRAS G12D-mutated, locally advanced unresectable or metastatic NSCLC who have not responded to standard treatment.

The trial is set to be conducted across more than 40 research centers in China. The first patient was recently enrolled at Nanjing Gulou Hospital, the company stated.

Expanding Clinical Program

This NSCLC trial is the second Phase III study for GFH375. The first, "Qilin-Yi 01," was initiated last year for pancreatic cancer and was reportedly the world's first pivotal trial for an oral KRAS G12D inhibitor in that indication.

Sample IUX Markets – In-articleAd

Earlier this year, GFH375 received two Breakthrough Therapy Designations (BTD) in China for its potential as a monotherapy in both KRAS G12D-mutated NSCLC and pancreatic cancer, signaling regulatory recognition of its potential to address a significant unmet need.

Market Significance and Outlook

Currently, there are no approved targeted therapies for patients with the KRAS G12D mutation. This patient population often shows lower sensitivity to chemotherapy and a poor response rate to PD-1/L1 immunotherapy inhibitors, leaving them with limited effective treatment options after first-line therapy.

GenFleet noted that GFH375 has demonstrated potential best-in-class efficacy among KRAS G12D inhibitors in development globally. The company plans to present the latest data from its NSCLC monotherapy study in an oral report at the upcoming World Conference on Lung Cancer (WCLC), a key potential catalyst for investors.

Read next

More on Stocks
Back to latest news

LATEST